治疗 IDH 突变胶质瘤的进展。

IF 4.1 2区医学 Q1 CLINICAL NEUROLOGY

Current Opinion in Neurology Pub Date : 2024-09-12 DOI:10.1097/wco.0000000000001316

Chooyoung Baek,Alice Laurenge,Mehdi Touat

{"title":"治疗 IDH 突变胶质瘤的进展。","authors":"Chooyoung Baek,Alice Laurenge,Mehdi Touat","doi":"10.1097/wco.0000000000001316","DOIUrl":null,"url":null,"abstract":"PURPOSE OF REVIEW\r\nIsocitrate dehydrogenase (IDH) mutation is a defining molecular driver of WHO grade 2-4 astrocytomas and oligodendrogliomas. In this article, we review the recent therapeutic approaches specifically targeting IDH-mutant gliomas and summarize ongoing clinical trials in this population.\r\n\r\nRECENT FINDINGS\r\nThe IDH inhibitor vorasidenib recently demonstrated its efficacy after surgical resection in grade 2 IDH-mutated gliomas. Several studies in patients with IDH-mutant gliomas are currently exploring various strategies to target IDH mutations, including the use of small-molecule inhibitors, immunotherapies, peptide vaccines and agents targeting metabolic and epigenomic vulnerabilities.\r\n\r\nSUMMARY\r\nMutant-IDH targeting holds significant promise in treating progressive or recurrent IDH-mutant gliomas. Recent results with IDH inhibitors will change practice and influence the existing guidelines in a near future.","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":"39 1","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in the treatment of IDH-mutant gliomas.\",\"authors\":\"Chooyoung Baek,Alice Laurenge,Mehdi Touat\",\"doi\":\"10.1097/wco.0000000000001316\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"PURPOSE OF REVIEW\\r\\nIsocitrate dehydrogenase (IDH) mutation is a defining molecular driver of WHO grade 2-4 astrocytomas and oligodendrogliomas. In this article, we review the recent therapeutic approaches specifically targeting IDH-mutant gliomas and summarize ongoing clinical trials in this population.\\r\\n\\r\\nRECENT FINDINGS\\r\\nThe IDH inhibitor vorasidenib recently demonstrated its efficacy after surgical resection in grade 2 IDH-mutated gliomas. Several studies in patients with IDH-mutant gliomas are currently exploring various strategies to target IDH mutations, including the use of small-molecule inhibitors, immunotherapies, peptide vaccines and agents targeting metabolic and epigenomic vulnerabilities.\\r\\n\\r\\nSUMMARY\\r\\nMutant-IDH targeting holds significant promise in treating progressive or recurrent IDH-mutant gliomas. Recent results with IDH inhibitors will change practice and influence the existing guidelines in a near future.\",\"PeriodicalId\":11059,\"journal\":{\"name\":\"Current Opinion in Neurology\",\"volume\":\"39 1\",\"pages\":\"\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/wco.0000000000001316\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/wco.0000000000001316","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

综述目的柠檬酸脱氢酶（IDH）突变是WHO 2-4级星形细胞瘤和少突胶质瘤的决定性分子驱动因素。在本文中，我们回顾了最近专门针对IDH突变胶质瘤的治疗方法，并总结了正在这一人群中进行的临床试验。最新发现IDH抑制剂vorasidenib最近证明了其在2级IDH突变胶质瘤手术切除后的疗效。目前有几项针对IDH突变胶质瘤患者的研究正在探索针对IDH突变的各种策略，包括使用小分子抑制剂、免疫疗法、多肽疫苗以及针对代谢和表观基因组脆弱性的药物。IDH抑制剂的最新研究成果将在不久的将来改变临床实践并影响现有指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Advances in the treatment of IDH-mutant gliomas.

PURPOSE OF REVIEW Isocitrate dehydrogenase (IDH) mutation is a defining molecular driver of WHO grade 2-4 astrocytomas and oligodendrogliomas. In this article, we review the recent therapeutic approaches specifically targeting IDH-mutant gliomas and summarize ongoing clinical trials in this population. RECENT FINDINGS The IDH inhibitor vorasidenib recently demonstrated its efficacy after surgical resection in grade 2 IDH-mutated gliomas. Several studies in patients with IDH-mutant gliomas are currently exploring various strategies to target IDH mutations, including the use of small-molecule inhibitors, immunotherapies, peptide vaccines and agents targeting metabolic and epigenomic vulnerabilities. SUMMARY Mutant-IDH targeting holds significant promise in treating progressive or recurrent IDH-mutant gliomas. Recent results with IDH inhibitors will change practice and influence the existing guidelines in a near future.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Opinion in Neurology 医学-临床神经学

CiteScore

8.60

自引率

0.00%

发文量

174

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Neurology is a highly regarded journal offering insightful editorials and on-the-mark invited reviews; covering key subjects such as cerebrovascular disease, developmental disorders, neuroimaging and demyelinating diseases. Published bimonthly, each issue of Current Opinion in Neurology introduces world renowned guest editors and internationally recognized academics within the neurology field, delivering a widespread selection of expert assessments on the latest developments from the most recent literature.